CAMBRIDGE, UK – 21 February 2022 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), announces that its CEO, Anker Lundemose, will attend and present at the next event in the BMO Biopharma Spotlight Series: Protein – Degraders and Other Next Gen Technologies, on Thursday, 24 February 2022.
The virtual event will focus on the therapeutic area of protein degraders and other emerging technologies, with an agenda consisting of fireside chats, expert presentations, and topical panels.
Dr Lundemose will be available for one-to-one meetings as well as presenting as part of the Private Company Spotlights panel and Q&A at 11.20 ET.
This will be the sixth event in the BMO Biopharma Spotlight series of webinars, which explore different therapeutic areas and enable KOLs, public companies, and key players in the private sector to discuss their scientific research and technological approaches.
FOR MORE INFORMATION:
|Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340
Melanie Toyne-Sewell / Katie Duffell
Tel: +44 (0) 20 7457 2013
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.
To date the Company has received £73 million / $101 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.